Bristol Myers Squibb Acquires Orbital: $1.5B Biotech Bet
Update: 2025-10-10
Description
Bristol Myers Squibb just dropped $1.5 billion to acquire Orbital Therapeutics, grabbing a front-row seat in the cell therapy revolution. Find out how this major pharma deal could reshape the future of medicine, impact investors, and accelerate the race for next-generation treatments.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
